Erythrocyte membrane vesicles coated biomimetic and targeted doxorubicin nanocarrier: Development, characterization and in vitro studies

Basit Öğe Kaydı
dc.contributor.authorGuliz, A. K.
dc.contributor.authorSanlier, Senay Hamarat
dc.date.accessioned2020-12-01T12:01:39Z
dc.date.available2020-12-01T12:01:39Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractOvarian cancer is the most common cause of death within gynecologic cancers and doxorubicin is an anthracycline agent, is widely used in many cancer types. Folate receptor enables of accumulation folate linked nanoparticles into tumor cells and magnetic targeting also provides localized addressing. the aim of this work is to develop a magnetic and biomolecularly targeted biomimetic doxorubicin nanocarrier system for ovarian cancer therapy. Firstly, highly dispersed starch and PEG diacid coated magnetic nanoparticles were synthesized with an easy and fabricable method and 91.45 +/- 1.07 mu g doxorubicin was adsorbed on per mg magnetic nanoparticles. the structure was verified with FTIR, TGA, VSM, TEM and zetasizer. Then, folate linked erythrocyte membrane vesicles were prepared from ghost cells and doxorubicin loaded magnetic nanoparticles were encapsulated into vesicles through extrusion due to enabling avoidance from immun clearance. the final nanocarrier system was nearly spherical in shape and had a hydrodynamic size of 157.4 +/- 33.2 nm. Drug release profile was determined as in a controlled manner and IC50 value against SKOV3 for 72 h was calculated as 0.74 +/- 0.32 mg/mL which was lower than that of free doxorubicin. in conclusion, it was suggested that biomimetic doxorubicin nanocarrier system have many advantages for targeted ovarian cancer therapy. (C) 2019 Elsevier B.V. All rights reserved.en_US
dc.description.sponsorshipResearch Foundation of Ege University, TurkeyEge University [2012 FEN 028]en_US
dc.description.sponsorshipThis work was supported by the Research Foundation of Ege University (grant number, 2012 FEN 028), Turkey. in addition I would like to acknowledge to Ege University Drug Development and Pharmacokinetics Research - Application Center (ARGEFAR) for the laboratorial support during my PhD thesis.en_US
dc.identifier.doi10.1016/j.molstruc.2019.127664
dc.identifier.issn0022-2860
dc.identifier.issn1872-8014
dc.identifier.issn0022-2860en_US
dc.identifier.issn1872-8014en_US
dc.identifier.scopus2-s2.0-85077314864en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.molstruc.2019.127664
dc.identifier.urihttps://hdl.handle.net/11454/62485
dc.identifier.volume1205en_US
dc.identifier.wosWOS:000511287400026en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Molecular Structureen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDoxorubicinen_US
dc.subjectMagnetiteen_US
dc.subjectBiomimetic nanoparticlesen_US
dc.subjectFolate receptoren_US
dc.subjectTargeted drug deliveryen_US
dc.subjectOvarian canceren_US
dc.titleErythrocyte membrane vesicles coated biomimetic and targeted doxorubicin nanocarrier: Development, characterization and in vitro studiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu